Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents

Recently, the single nucleotide polymorphism (SNP) identified as rs1260326, in the glucokinase regulatory protein (GCKR), was associated with hypertriglyceridemia in adults. Because accumulation of triglycerides in hepatocytes represents the hallmark of steatosis, we aimed to investigate whether this variant might be associated with fatty liver (hepatic fat content, HFF%). Moreover, because recently rs738409 in the PNPLA3 and rs2854116 in the APOC3 were associated with fatty liver, we explored how the GCKR SNP and these two variants jointly influence hepatosteatosis. We studied 455 obese children and adolescents (181 Caucasians, 139 African Americans, and 135 Hispanics). All underwent an oral glucose tolerance test and fasting lipoprotein subclasses measurement by proton nuclear magnetic resonance. A subset of 142 children underwent a fast gradient magnetic resonance imaging to measure the HFF%. The rs1260326 was associated with elevated triglycerides (Caucasians P = 0.00014; African Americans P = 0.00417), large very low‐density lipoprotein (VLDL) (Caucasians P = 0.001; African Americans, P = 0.03), and with fatty liver (Caucasians P = 0.034; African Americans P = 0.00002; and Hispanics P = 0.016). The PNPLA3, but not the APOC3 rs2854116 SNP, was associated with fatty liver but not with triglyceride levels. There was a joint effect between the PNPLA3 and GCKR SNPs, explaining 32% of HFF% variance in Caucasians (P = 0.00161), 39.0% in African Americans (P = 0.00000496), and 15% in Hispanics (P = 0.00342). Conclusion: The rs1260326 in GCKR is associated with hepatic fat accumulation along with large VLDL and triglyceride levels. GCKR and PNPLA3 act together to convey susceptibility to fatty liver in obese youths. (Hepatology 2012)

[1]  M. Zappa,et al.  The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. , 2011, Journal of hepatology.

[2]  Jonathan C. Cohen,et al.  Expression and Characterization of a PNPLA3 Protein Isoform (I148M) Associated with Nonalcoholic Fatty Liver Disease* , 2011, The Journal of Biological Chemistry.

[3]  F. Leonetti,et al.  Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans , 2011, Lipids in Health and Disease.

[4]  David M. Evans,et al.  Association of Genetic Loci With Glucose Levels in Childhood and Adolescence , 2011, Diabetes.

[5]  Udo Hoffmann,et al.  Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits , 2011, PLoS genetics.

[6]  Jonathan C. Cohen,et al.  Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance , 2011, Hepatology.

[7]  B. Nordestgaard,et al.  TRIB1 and GCKR Polymorphisms, Lipid Levels, and Risk of Ischemic Heart Disease in the General Population , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Hongyu Zhao,et al.  A common variant in the patatin‐like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents , 2010, Hepatology.

[9]  A. Alisi,et al.  I148M patatin‐like phospholipase domain‐containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease , 2010, Hepatology.

[10]  Jonathan C. Cohen,et al.  Patatin‐like phospholipase domain‐containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease , 2010, Hepatology.

[11]  B. Chang,et al.  Patatin‐like phospholipase domain‐containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease , 2010, Hepatology.

[12]  S. Caprio,et al.  Ethnic differences in lipoprotein subclasses in obese adolescents: importance of liver and intraabdominal fat accretion. , 2010, The American journal of clinical nutrition.

[13]  S. Caprio,et al.  Central Role of Fatty Liver in the Pathogenesis of Insulin Resistance in Obese Adolescents , 2010, Diabetes Care.

[14]  A. Kotronen,et al.  Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein , 2010, Current opinion in lipidology.

[15]  Jonathan C. Cohen,et al.  A feed-forward loop amplifies nutritional regulation of PNPLA3 , 2010, Proceedings of the National Academy of Sciences.

[16]  W. März,et al.  Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study. , 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[17]  L. N. Valenti,et al.  Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease , 2010, Gut.

[18]  Nick V. Grishin,et al.  A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis , 2009, The Journal of Biological Chemistry.

[19]  Nicola L. Beer,et al.  The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver , 2009, Human molecular genetics.

[20]  J. Benson,et al.  The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years , 2009, Gut.

[21]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[22]  J. Schwimmer,et al.  Cardiovascular Risk Factors and the Metabolic Syndrome in Pediatric Nonalcoholic Fatty Liver Disease , 2008, Circulation.

[23]  E. Ford,et al.  Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002. , 2008, The Journal of pediatrics.

[24]  R. Collins,et al.  Newly identified loci that influence lipid concentrations and risk of coronary artery disease , 2008, Nature Genetics.

[25]  Marcia M. Nizzari,et al.  Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels , 2007, Science.

[26]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[27]  F. Matschinsky.  Regulation of Pancreatic β-Cell Glucokinase: From Basics to Therapeutics , 2002 .

[28]  M. Kaleko,et al.  Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein. , 2001, Diabetes.

[29]  J. Breslow,et al.  An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  F M Matschinsky,et al.  Glucokinase as Glucose Sensor and Metabolic Signal Generator in Pancreatic β-Cells and Hepatocytes , 1990, Diabetes.

[31]  L. N. Valenti,et al.  Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[32]  B. Melegh,et al.  GCKR gene functional variants in type 2 diabetes and metabolic syndrome: do the rare variants associate with increased carotid intima-media thickness? , 2010, Cardiovascular diabetology.

[33]  F. Matschinsky.  Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. , 2002, Diabetes.